Method of treating type 1 diabetes by administering NKp46 polypeptide

Ofer Mandelboim (Inventor), Angel Porgador (Inventor), Yaakov Naparstek (Inventor), Chamutal Gur (Inventor)

Research output: Patent

Abstract

The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
Original languageEnglish GB
Patent numberUS8980244B2
StatePublished - 1 Mar 2015

Fingerprint

Dive into the research topics of 'Method of treating type 1 diabetes by administering NKp46 polypeptide'. Together they form a unique fingerprint.

Cite this